Saúdská Arábie - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose - solution for injection - 40 %

Saúdská Arábie - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride,potassium chloride - solution - 5,0.45,0.15 %,

Saúdská Arábie - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride,potassium chloride - solution - 5,0.45,0.15 %,

Saúdská Arábie - angličtina - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose - solution for injection - 10 %

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - water for injection 100% - solution for injection - active: water for injection 100% - water for injections is used to dissolve or dilute substances or preparations for parenteral administration. water for injections may also be used as an irrigating solution for small wounds or during minor surgical procedures.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - irinotecan hydrochloride trihydrate, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: distearoylphosphatidylcholine; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; hepes; sodium chloride; water for injections; sucrosofate - onivyde is indicated:,? in combination with oxaliplatin and 5 fluorouracil (5 fu) and leucovorin (lv) for the first-line treatment of metastatic pancreatic adenocarcinoma.,? in combination with 5-fu and lv for the treatment of metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy.

Kanada - angličtina - Health Canada

baxter corporation - dextrose; sodium chloride - solution - 10g; 900mg - dextrose 10g; sodium chloride 900mg - replacement preparations

Kanada - angličtina - Health Canada

baxter corporation - lidocaine hydrochloride; dextrose - solution - 4mg; 50mg - lidocaine hydrochloride 4mg; dextrose 50mg - class ib antiarrythmics

Spojené státy - angličtina - NLM (National Library of Medicine)

international medication systems, limited - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dextrose monohydrate 500 mg in 1 ml - 50% dextrose injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. the solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. slow infusion of hypertonic solutions is essential to ensure proper utilization of dextrose and avoid production of hyperglycemia. a concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated. dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

Spojené státy - angličtina - NLM (National Library of Medicine)

general injectables & vaccines, inc - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dextrose monohydrate 25 g in 50 ml - 50% dextrose injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. the solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. a concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated. dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.